Lazar, Vladimir http://orcid.org/0000-0003-2375-1088
Magidi, Shai
Girard, Nicolas
Savignoni, Alexia http://orcid.org/0000-0003-0009-3174
Martini, Jean-François
Massimini, Giorgio
Bresson, Catherine
Berger, Raanan
Onn, Amir
Raynaud, Jacques
Wunder, Fanny
Berindan-Neagoe, Ioana http://orcid.org/0000-0001-5828-1325
Sekacheva, Marina
Braña, Irene
Tabernero, Josep http://orcid.org/0000-0002-2495-8139
Felip, Enriqueta
Porgador, Angel
Kleinman, Claudia
Batist, Gerald
Solomon, Benjamin
Tsimberidou, Apostolia Maria http://orcid.org/0000-0003-2713-233X
Soria, Jean-Charles
Rubin, Eitan
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Schilsky, Richard L. http://orcid.org/0000-0003-4474-4303
Article History
Received: 14 August 2020
Accepted: 26 March 2021
First Online: 28 April 2021
Competing interests
: Dr. Vladimir Lazar, Catherine Bresson, and Fanny Wunder, are full-time employees of Worldwide Innovative Network (WIN) Association—WIN Consortium. Worldwide Innovative Network (WIN) Association—WIN Consortium is the owner of the patent family entitled Digital Display. The inventors are Dr. Vladimir Lazar, and Shai Magidi . Shai Magidi receives consultancy from Worldwide Innovative Network (WIN) Association—WIN Consortium. Dr. Jean-François Martini is a full-time employee and stockholder of Pfizer Inc. Dr. Amir Onn receives consulting fees from Roche Israel, MSD Israel, Boehringer Ingelheim, and AstraZeneca. Dr. Giorgio Massimini is employee and shareholder of Merck KGaA, consulting for The Helleday Foundation (for free), shareholder of Hoffmann-LaRoche and Calithera. Dr. Irene Braña receives consultant fees from Orion Pharma, receives speaking fees from BMS, AstraZeneca, and Merck Serono, and is principal investigator and receives funding for clinical trials from AstraZeneca, BMS, Celgene, Gliknik, GSK, Janssen, KURA, MSD, Novartis, Orion Pharma, and Pfizer. Dr. Raanan Berger receives consulting fees from Roche, MSD, AstraZeneca, and BMS. Dr. Josep Tabernero declares scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-LaRoche Ltd., Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS, and Roche Diagnostics. Dr. Enriqueta Felip receives advisory board and/or speaker’s bureau fee from AbbVie, Amgen, AstraZeneca, Bayer, BluePrint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, PeerVoice, Pfizer, priME Oncology, Puma Biotechnology, Roche, Sanofi Genzyme, Springer, Takeda, and Touchime; on the board of Grifols, Independent member. Receives research funding from Fundacion Merck Salud, Grant for Oncology Innovation (GOI) EMD Serono. Prof. Angel Porgador declares scientific consultancy role for PiNK Biopharma. Dr. Gerald Batist collaborates in formal clinical trial contracts, IITs and in joint grants funded by Canadian and Quebec governments with Roche, Merck, Novartis, AstraZeneca, Bayer, Esperas, Aurka, Caprion, and MRM. Dr. Benjamin Solomon received honorarium for Advisory Board for AstraZeneca. Prof. Apostolia Maria Tsimberidou receives research funding (her institution) from Immatics Biotechnologies, Parker Institute for Cancer Immunotherapy, OBI Pharmaceuticals, Karus Therapeutics, Ltd., Tempus, Inc. CPRIT, Tvardi Therapeutics, EMD Serono, and Boston Biomedical. Inc. She also receives support from Philanthropic Funds. She has received consulting fees from Genentech, Covance, and Tempus (past 2 years). Dr. Razelle Kurzrock receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq, and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Neomed, Pfizer, Actuate Therapeutics, Roche, Turning Point Therapeutics, TD2/Volastra, and Bicara Therapeutics, Inc., has an equity interest in IDbyDNA and CureMatch Inc, serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. Dr. Richard. L. Schilsky .’s institution (ASCO) receives research grants in support of a clinical trial that he directs from the following companies: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Pfizer. The remaining authors declare no competing interests.